A network meta-analysis of the efficacy and side effects of UDCA-based therapies for primary sclerosing cholangitis

• Published in: Oncotarget Vol. 6; no. 29; pp. 26757 - 26769
• Main Authors: Zhu, Gui-Qi, Shi, Ke-Qing, Huang, Gui-Qian, Wang, Li-Ren, Lin, Yi-Qian, Braddock, Martin, Chen, Yong-Ping, Zhou, Meng-Tao, Zheng, Ming-Hua
• Format: Journal Article
• Language: English
• Published: United States Impact Journals LLC 29.09.2015
• Subjects: Adult; Aged; Alkaline Phosphatase - blood; Bilirubin - blood; Cholagogues and Choleretics - administration & dosage; Cholangitis, Sclerosing - therapy; Disease Progression; Humans; Liver - pathology; Liver Transplantation; Metronidazole - administration & dosage; Middle Aged; Mycophenolic Acid - administration & dosage; Mycophenolic Acid - analogs & derivatives; Odds Ratio; Proportional Hazards Models; Randomized Controlled Trials as Topic; Research Design; Research Paper: Pathology; Severity of Illness Index; Treatment Outcome; Ursodeoxycholic Acid - administration & dosage; Young Adult; Pathology Section; adverse events; clinical efficacy; intervention; network meta-analysis; primary sclerosing cholangitis
• ISSN: 1949-2553; 1949-2553
• DOI: 10.18632/oncotarget.5610

Therapies for treatment of patients with primary sclerosing cholangitis (PSC) include administration of ursodeoxycholic acid (UDCA) alone, or combination with metronidazole (MTZ) or mycophenolate mofetil (MMF), respectively. However, the optimum regimen still remains inconclusive. We aimed to compare interventions in terms of patient mortality or liver transplantation (MOLT), progression of liver histological stage (POLHS), serum bilirubin, alkaline phosphatase (ALP) levels and adverse events (AE). We searched PubMed, Embase and the Cochrane Library for randomized controlled trials until 31, Jan 2015. We estimated hazard ratios (HRs), odds ratios (ORs) and mean difference (MD) between treatments on clinical outcomes. Sensitivity analyses based on the dose of UDCA, quality of trials or treatment duration were also performed. Ten RCTs were included. Compared with UDCA plus MTZ, UDCA (HR 0.28, 95%CI 0.01-3.41), UDCA plus MMF (HR 0.08, 95%CI 0.00-4.18), or OBS (HR 0.28, 95%CI 0.01-3.98) all provided an increased risk of MOLT. UDCA provided a significant reduction in bilirubin and ALP levels compared with OBS (MD -13.92, P < 0.001; MD -484.34, P < 0.001; respectively). With respect to POLHS, although differing not significantly, UDCA plus MTZ had a tendency to improve LHS more than UDCA (OR 1.33), UDCA plus MMF (OR 3.24) or OBS (OR 1.08). Additionally, UDCA plus MTZ (MD -544.66, P < 0.001) showed a significant reduction in ALP levels compared with OBS, but appeared to be associated with more AEs compared with UDCA (OR 5.09), UDCA plus MMF (OR 4.80) or OBS (OR 7.21). MTZ plus UDCA was the most effective therapy in survival rates and liver histological progression.